PapGene, Inc. Awarded Grant for Test to Detect Ovarian and Endometrial Cancers

PapGene, Inc. announced that it was recently awarded a highly competitive Fast-Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute of the National Institutes of Health to commercialize a test to detect ovarian and endometrial cancers.
According to the company:

The funds for this Fast-Track grant will be released in two phases, which together have the potential to provide a total of nearly $2.3 million in resources to PapGene’s test commercialization efforts. Phase I will provide $297,000 to the company to demonstrate the accuracy of the test and its clinical validity. Upon successful completion of Phase I, Phase II will provide approximately $2 million to demonstrate the clinical utility of the test and to launch its regulatory approval process.

Howie Kaufman, CEO of PapGene commented:

Detecting cancer early is the key to its successful treatment. We are very excited that this award will help PapGene commercialize our innovative genetic testing technology and provide a significant new tool for detecting cancers while they are still in a curable stage.

Click here to view the full press release.